Diltiazem alone and combined with nitroglycerin: effect on normal and diseased human coronary arteries

O M Hess1, H Nonogi, A Bortone

  • 1Department of Internal Medicine, University Hospital, Zurich, Switzerland.

European Heart Journal
|November 1, 1989
PubMed

Insights

Diltiazem and nitroglycerin both dilate normal coronary arteries. However, diltiazem pretreatment enhanced nitroglycerin

Area of Science:

  • Cardiology
  • Vascular Physiology

Background:

  • Coronary artery disease (CAD) affects large epicardial vessels.
  • Vasodilators are crucial for managing CAD symptoms.

Purpose of the Study:

  • To evaluate the vasodilatory effects of diltiazem and nitroglycerin on normal and stenotic coronary arteries in patients with CAD.
  • To compare the effects of diltiazem pretreatment on coronary vasodilation during exercise and nitroglycerin administration.

Main Methods:

  • Biplane quantitative coronary arteriography was used to measure luminal area in 26 CAD patients.
  • Measurements were taken at rest, after intracoronary diltiazem, during exercise, and after sublingual nitroglycerin.
  • Patients were divided into a control group and a diltiazem-pretreated group.

Main Results:

  • Both diltiazem and nitroglycerin increased luminal area in normal vessels.
  • In stenotic vessels, exercise decreased luminal area, while nitroglycerin increased it slightly in controls.
  • Diltiazem pretreatment led to a greater vasodilatory response to nitroglycerin in stenotic segments compared to controls.

Conclusions:

  • Diltiazem and nitroglycerin effectively dilate normal coronary arteries in CAD patients.
  • Diltiazem pretreatment enhances the vasodilatory effect of nitroglycerin on stenotic coronary arteries.
  • These findings suggest potential benefits of combined vasodilator therapy in managing coronary stenosis.

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...